Last reviewed · How we verify
Ezetimibe and raltegravir
Ezetimibe and raltegravir is a Small molecule drug developed by St Stephens Aids Trust. It is currently in Phase 1 development.
At a glance
| Generic name | Ezetimibe and raltegravir |
|---|---|
| Sponsor | St Stephens Aids Trust |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Raltegravir and Ezetimibe PK Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ezetimibe and raltegravir CI brief — competitive landscape report
- Ezetimibe and raltegravir updates RSS · CI watch RSS
- St Stephens Aids Trust portfolio CI
Frequently asked questions about Ezetimibe and raltegravir
What is Ezetimibe and raltegravir?
Ezetimibe and raltegravir is a Small molecule drug developed by St Stephens Aids Trust.
Who makes Ezetimibe and raltegravir?
Ezetimibe and raltegravir is developed by St Stephens Aids Trust (see full St Stephens Aids Trust pipeline at /company/st-stephens-aids-trust).
What development phase is Ezetimibe and raltegravir in?
Ezetimibe and raltegravir is in Phase 1.
Related
- Manufacturer: St Stephens Aids Trust — full pipeline
- Compare: Ezetimibe and raltegravir vs similar drugs
- Pricing: Ezetimibe and raltegravir cost, discount & access